Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeradigmSTU:AL21 23 Return-on-Tangible-Asset is -7.55% as of Dec. 2022. GuruFocus rates STU:AL21 with a GF Score™ of 23/100. Among 681 Healthcare Providers & Services companies, Veradigm ranks worse than 146842.73% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Veradigm's annualizedNet Income for the quarter that ended in Dec. 2022 was €-81.6 Mil. Veradigm's average total tangible assets for the quarter that ended in Dec. 2022 was €1,081.2 Mil. Therefore, Veradigm's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2022 was -7.55%.
The historical rank and industry rank for Veradigm's Return-on-Tangible-Asset or its related term are showing as below:
STU:AL21's Return-on-Tangible-Asset is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.7 * Ranked among companies with meaningful Return-on-Tangible-Asset only.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Veradigm Return-on-Tangible-Asset Related Terms
Veradigm Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Veradigm's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AL21 vs WEAV, PHR, SOPH: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Veradigm's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veradigm Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Veradigm's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Dec. 2022) net income data.
What does a Return-on-Tangible-Asset of -7.55% mean?
Veradigm (STU:AL21) has a Return-on-Tangible-Asset of -7.55% as of Dec. 2022. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #999999 out of 681 companies in the Healthcare Providers & Services industry.
Is Veradigm's Return-on-Tangible-Asset too high?
Veradigm's current Return-on-Tangible-Asset is -7.55%. Based on the distribution chart, Veradigm ranks #999999 out of 681 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's Return-on-Tangible-Asset compare to WEAV and PHR?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 681 companies for Return-on-Tangible-Asset. This places Veradigm in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.70, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Veradigm and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current Return-on-Tangible-Asset is -7.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current Return-on-Tangible-Asset of -7.55%. The current Return-on-Tangible-Asset is -7.55%. Veradigm's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Veradigm (STU:AL21), the current Return-on-Tangible-Asset is -7.55% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
23GF Score
Get the complete analysis for STU:AL21
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AL21 has been successfully added to your 
